Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which provides disease-modifying solutions for neurodegenerative diseases. The firm focuses on streamlined clinical development and drug discovery. It specializes in developing a proprietary therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases that target the neuroinflammation and nerve cell death that characterize these disorders. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amylyx Pharmaceuticals excels in Q4 with RELYVRIO launch success

Amylyx Pharmaceuticals demonstrated strong financial performance in Q4 2022, driven by the successful commercial launch of RELYVRIO for ALS treatment.
The company's focus on key priorities for the U.S. launch and commitment to serving ALS patients position it well for future growth and impact.
While facing challenges in meeting analyst expectations and study success criteria, Amylyx Pharmaceuticals remains optimistic about the opportunities ahead in advancing ALS treatment.

Amylyx Pharmaceuticals achieves profitability in Q1, plans global PSP study

Amylyx Pharmaceuticals delivered strong financial performance in Q1, driven by the success of RELYVRIO and plans for AMX0035 in PSP. While facing challenges in profitability expectations and pipeline expansion, the company is well-positioned to capitalize on opportunities for growth and impact.

Amylyx Pharmaceuticals reports robust Q2 performance and strategic growth focus

Amylyx Pharmaceuticals' Q2 2023 Earnings Call highlighted strong financials, patient-centric initiatives, and advancements in R&D programs for neurodegenerative diseases.
Analysts' inquiries underscored the need for clarity on compliance rates, expansion strategies, and study design considerations to address potential challenges.
The company's emphasis on trial design strength, patient support, and market positioning opportunities signals a strategic focus on growth and innovation.

Amylyx Pharmaceuticals reports strong Q3 earnings, eyes growth opportunities

Amylyx Pharmaceuticals had a strong Q3 performance with significant net product revenues and a focus on expanding patient reach. While facing challenges in discontinuations and revenue impact, the company is optimistic about growth opportunities through education and trial results.

Amylyx Pharmaceuticals reports robust earnings, poised for market expansion

Amylyx Pharmaceuticals had a successful year financially, with strong revenue growth and a solid financial position.
The company's focus on expanding market reach, developing innovative biomarkers, and enhancing disease diagnosis underscores their commitment to advancing ALS treatment.
While facing uncertainties with upcoming trial data and regulatory challenges, Amylyx remains optimistic about growth opportunities and R&D advancements.

Amylyx Pharmaceuticals adapts strategy post-PHOENIX trial, eyes regulatory milestones

Amylyx Pharmaceuticals navigated a challenging quarter with a focus on pipeline diversification and strategic planning for multiple neurodegenerative diseases. Despite setbacks in the PHOENIX trial, the company remains resilient and proactive in addressing challenges while seizing opportunities for growth and regulatory progress.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024.

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX) securities between November 11, 2022 and November 8, 2023, inclusive (the “Class Period”). Amylyx investors have until April 9, 2024 to file a lead plaintiff motion. If you suffered a loss on your.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc. (AMLX) Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX) investors concerning the Company's possible violations of federal securities laws. On November 9, 2023, Amylyx released its third quarter 2023 financial results, missing GAAP earnings per share consensus estimates by approximately 29%. The Company stated that results were impacted by a “slowdown in net adds” for its ALS tr.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Amylyx Pharmaceuticals, Inc. (AMLX) on Behalf of Investors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals to Presents Updates on AMX0114 and RELYVRIO® Programs in ALS at the 2024 MDA Clinical and Scientific Conference.

Amylyx Pharmaceuticals to Present Updates on its AMX0114 and RELYVRIO® Programs in ALS at the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference

NEW YORK , Feb. 15, 2024 /PRNewswire/ --  The Gross Law Firm issues the following notice to shareholders of Amylyx Pharmaceuticals, Inc.. Shareholders who purchased shares of AMLX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Lost Money on Amylyx Pharmaceuticals, Inc.(AMLX)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Amylyx investments or would like to inquire about potentially pursuing claims to recover your loss under the federal secur.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Amylyx Pharmaceuticals, Inc. (AMLX) on Behalf of Investors

SAN DIEGO--(BUSINESS WIRE)---- $AMLX #AmylyxPharmaceuticalsInc--Robbins LLP is Investigating the Allegations Against Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. (AMLX) Stockholder Alert: Robbins LLP Reminds Stockholders of Amylyx Pharmaceuticals, Inc. Class Action

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On November 9, 2023, Amylyx released its third quarter 2023 financial results, missing GAAP earnings per share consensus estimates by approximately 29%. The Company.

The Law Offices of Frank R. Cruz Announces Investigation of Amylyx Pharmaceuticals, Inc. (AMLX) on Behalf of Investors

NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 9, 2024 to file lead plaintiff applications in a securities class action lawsuit against Amylyx Pharmaceuticals, Inc. (NasdaqGS: AMLX), if they purchased the Company's securities between November 11, 2022 and November 8, 2023, inclusive (the “Class Period”). This action is pending in the United States District C.

AMYLYX PHARMACEUTICALS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. - AMLX

NEW YORK, NY / ACCESSWIRE / February 13, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/amylyx-lawsuit-submission-form?prid=66975&wire=1 or contact Joseph E. Levi, Esq.

Lost Money on Amylyx Pharmaceuticals, Inc. (AMLX)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky

NEW YORK--(BUSINESS WIRE)---- $AMLX #ClassActionLawsuit--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of those who acquired Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ:AMLX) securities during the period of November 11, 2022 to November 8, 2023, inclusive (“the Class Period”). Investors have until April 4, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit. [Clic.

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc. (AMLX) Investors

BeiGene

MiMedx Group

I have always said it, and I keep my word regarding the biotechnology sector, since it is one of the largest and most important sectors. Not only is it vital for the financial markets, but for the quality of human life.

Get Rich Quick With These 3 Biotech Stocks to Buy Now

NEW YORK, NY / ACCESSWIRE / February 13, 2024 / If you suffered a loss on your Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/amylyx-lawsuit-submission-form?prid=66937&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that Lost Money on Amylyx Pharmaceuticals, Inc. (AMLX) Should Contact Levi & Korsinsky about Pending Class Action - AMLX

NEW YORK , Feb. 12, 2024 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) between November 11, 2022 and November 8, 2023, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMLX

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) between November 11, 2022 and November 8, 2023, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 9, 2024. SO WHAT: If you purchased Amylyx securities during th.

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMLX

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Amylyx business and prospects, resulting in its stock trading at inflated prices.

AMLX INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Amylyx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

AMLX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Amylyx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Amylyx Class Action Lawsuit

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces Completion of Enrollment in HELIOS, a Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome.

Amylyx Pharmaceuticals Announces Completion of Enrollment in HELIOS, a Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome

Puma Biotechnology

Cassava Sciences Inc

There's a reason that many biotech investors prefer to stick with large-cap stocks. Investing in small-cap biotech stocks is not for risk-averse investors.

3 small-cap biotechs with potential breakthroughs in 2024

Neurocrine Biosciences

Investors with an interest in Medical - Drugs stocks have likely encountered both Amylyx Pharmaceuticals, Inc. (AMLX) and Neurocrine Biosciences (NBIX). But which of these two companies is the best option for those looking for undervalued stocks?

AMLX vs. NBIX: Which Stock Should Value Investors Buy Now?

Agenus

Eli Lilly

After being mostly down over the past three years, the biotech sector rallied hard to end 2023. The SPDR S&P Biotech ETF (NYSEARCA: XBI ) is up 31% in the last three months.

3 Biotech Stocks with Potential for Major Medical Breakthroughs in 2024

Exelixis

Bio-Techne

Stocks in the biotech sector are always going to have massive potential. Health is arguably the most important aspect of life.

3 Top-Rated Biotech Stocks Wall Street Analysts Are Loving Now: January 2024

Boston Scientific

CRISPR Therapeutics

Globus Medical

iRhythm Technologies

Moderna

Teladoc

While the technology sector – especially regarding artificial intelligence – may have captured the spotlight, investors ought to consider adding healthcare stocks to their portfolio. If I had to boil it down to one phrase, it would be permanent relevance.

7 Healthcare Stocks Taking Medicine to the Next Level

Vertex Pharmaceuticals

Vertex Pharmaceuticals' cystic fibrosis franchise is successful, but it's also running out of room to grow. Expected results from a trial with an experimental pain reliever called VX-548 could push Vertex Pharmaceuticals' stock price much higher in 2024.

2 Biotech Stocks With Huge Catalysts in 2024

Amylyx Therapeutics shares have limited downside ahead of a Phase 3 trial of Relyvrio, an ALS treatment candidate, according to Baird. Analysts have initiated coverage on the stock with an Outperform rating and a $37 price target.

News for Amylyx Pharmaceuticals Stock (AMLX)